The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen

Cancer

Volumn 122, Issue 23, 2016, Pages 3682-3686

  Silver, Michelle I ^a   Schiffman, Mark ^a   Fetterman, Barbara ^b   Poitras, Nancy E ^b   Gage, Julia C ^a   Wentzensen, Nicolas ^a   Lorey, Thomas ^b   Kinney, Walter K ^c   Castle, Philip E ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

biopsy; cervical cancer; cervical intraepithelial neoplasia; colposcopy; cotest; human papillomavirus; screening

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PRECANCER; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMPLICATION; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES; RISK FACTOR; RISK REDUCTION; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

ADULT; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RISK FACTORS; RISK REDUCTION BEHAVIOR; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84995770352     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30277     Document Type: Article

References (13)

1. Moyer VA; US Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880–891.
2. Saslow D, Solomon D, Lawson HW, et al; American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516–542.
3. Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin Number 131: screening for cervical cancer. Obstet Gynecol. 2012;120:1222–1238.
4. Practice Bulletin No. 157 Summary: cervical cancer screening and prevention. Obstet Gynecol. 2016;127:185–187.
5. Mayrand MH, Duarte-Franco E, Rodrigues I, et al; Canadian Cervical Cancer Screening Trial Study Group. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357:1579–1588.
6. Dillner J, Rebolj M, Birembaut P, et al; Joint European Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
7. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764–1772.
8. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385–1394.
9. Ronco G, Dillner J, Elfstrom KM, et al; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of 4 European randomised controlled trials. Lancet. 2014;383:524–532.
10. Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014;106:dju153.
11. Kinney W, Wright TC, Dinkelspiel HE, DeFrancesco M, Thomas Cox J, Huh W. Increased cervical cancer risk associated with screening at longer intervals. Obstet Gynecol. 2015;125:311–315.
12. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663–672.
13. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN3 + risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5 suppl 1):S28–S35.